- Home
- INM vs REVB Comparison
INM vs REVB Comparison
Compare INM & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INM
- REVB
- Stock Information
- Founded
- INM 1981
- REVB 2020
- Country
- INM Canada
- REVB United States
- Employees
- INM N/A
- REVB N/A
- Industry
- INM Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- INM Health Care
- REVB Health Care
- Exchange
- INM Nasdaq
- REVB Nasdaq
- Market Cap
- INM 2.3M
- REVB 2.3M
- IPO Year
- INM N/A
- REVB N/A
- Fundamental
- Price
- INM $2.08
- REVB $2.67
- Analyst Decision
- INM
- REVB
- Analyst Count
- INM 0
- REVB 0
- Target Price
- INM N/A
- REVB N/A
- AVG Volume (30 Days)
- INM 15.0K
- REVB 141.4K
- Earning Date
- INM 05-13-2025
- REVB 03-06-2025
- Dividend Yield
- INM N/A
- REVB N/A
- EPS Growth
- INM N/A
- REVB N/A
- EPS
- INM N/A
- REVB N/A
- Revenue
- INM $4,832,013.00
- REVB N/A
- Revenue This Year
- INM N/A
- REVB N/A
- Revenue Next Year
- INM N/A
- REVB N/A
- P/E Ratio
- INM N/A
- REVB N/A
- Revenue Growth
- INM N/A
- REVB N/A
- 52 Week Low
- INM $1.99
- REVB $2.36
- 52 Week High
- INM $15.70
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- INM 26.67
- REVB 32.04
- Support Level
- INM $1.99
- REVB $2.51
- Resistance Level
- INM $2.66
- REVB $2.92
- Average True Range (ATR)
- INM 0.15
- REVB 0.27
- MACD
- INM -0.05
- REVB 0.03
- Stochastic Oscillator
- INM 9.34
- REVB 28.44
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).